Amring Pharms Drug Patent Portfolio
Amring Pharms owns 1 orange book drug protected by 8 US patents Given below is the list of Amring Pharms's drug patents along with their expiration dates.
| Drug Patent Number | Drug Patent Title | Drug Patent Expiry | Status |
|---|---|---|---|
| US7947739 | Tranexamic acid formulations | 04 Mar, 2025 | Expired |
| US8022106 | Tranexamic acid formulations | 04 Mar, 2025 | Expired |
| US8273795 | Tranexamic acid formulations | 04 Mar, 2025 | Expired |
| US8487005 | Tranexamic acid formulations | 04 Mar, 2025 | Expired |
| US8791160 | Tranexamic acid formulations | 04 Mar, 2025 | Expired |
| US8809394 | Tranexamic acid formulations | 04 Mar, 2025 | Expired |
| US8957113 | Tranexamic acid formulations | 04 Mar, 2025 | Expired |
| US9060939 | Tranexamic acid formulations | 04 Mar, 2025 | Expired |
Latest Legal Activities on Amring Pharms's Drug Patents
Given below is the list of recent legal activities going on the following drug patents of Amring Pharms.
| Activity | Date | Patent Number |
|---|---|---|
 | ||
| Payment of Maintenance Fee, 12th Year, Large Entity | 17 Nov, 2023 | US8273795 |
| Payment of Maintenance Fee, 12th Year, Large Entity | 04 Nov, 2022 | US8022106 (Litigated) |
|
Correspondence Address Change
Critical
| 18 Oct, 2022 | US8022106 (Litigated) |
|
Correspondence Address Change
Critical
| 18 Oct, 2022 | US8273795 |
|
Correspondence Address Change
Critical
| 18 Oct, 2022 | US8809394 |
|
Correspondence Address Change
Critical
| 18 Oct, 2022 | US8791160 |
|
Correspondence Address Change
Critical
| 18 Oct, 2022 | US9060939 |
|
Correspondence Address Change
Critical
| 18 Oct, 2022 | US8487005 |
| Payment of Maintenance Fee, 8th Year, Large Entity | 16 Aug, 2022 | US9060939 |
| Payment of Maintenance Fee, 12th Year, Large Entity | 16 Aug, 2022 | US7947739 |
| Payment of Maintenance Fee, 8th Year, Large Entity | 06 Jan, 2022 | US8791160 |
| Payment of Maintenance Fee, 8th Year, Large Entity | 06 Jan, 2022 | US8809394 |
| Payment of Maintenance Fee, 8th Year, Large Entity | 05 Jan, 2021 | US8487005 |
| Payment of Maintenance Fee, 8th Year, Large Entity | 19 Mar, 2020 | US8273795 |
| Payment of Maintenance Fee, 8th Year, Large Entity | 12 Mar, 2019 | US8022106 (Litigated) |
Amring Pharms's Family Patents
Amring Pharms Drug List
Given below is the complete list of Amring Pharms's drugs and the patents protecting them.
1. Lysteda
Lysteda is protected by 8 patents, out of which all have expired. Check out its patent list below.
| Drug Patent Number | Drug Patent Title | Drug Patent Expiry | Status |
|---|---|---|---|
| US7947739 | Tranexamic acid formulations |
04 Mar, 2025
(7 months ago)
| Expired |
| US8022106 | Tranexamic acid formulations |
04 Mar, 2025
(7 months ago)
| Expired |
| US8273795 | Tranexamic acid formulations |
04 Mar, 2025
(7 months ago)
| Expired |
| US8487005 | Tranexamic acid formulations |
04 Mar, 2025
(7 months ago)
| Expired |
| US8791160 | Tranexamic acid formulations |
04 Mar, 2025
(7 months ago)
| Expired |
| US8809394 | Tranexamic acid formulations |
04 Mar, 2025
(7 months ago)
| Expired |
| US8957113 | Tranexamic acid formulations |
04 Mar, 2025
(7 months ago)
| Expired |
| US9060939 | Tranexamic acid formulations |
04 Mar, 2025
(7 months ago)
| Expired |
Discover which of these patents contain the active ingredient(API) of the drug, their family patents, along with litigation and legal activity details of these patents on Lysteda's drug page